Gaze Contingent Feedback in Major Depressive Disorder (MDD)
NCT ID: NCT02945735
Last Updated: 2019-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2016-11-06
2019-01-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
gaze-contingent
Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
Attention Modification
Feedback according to participants' viewing patterns, in order to modify their attention.
non-gaze contingent
Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
Attention Modification
Feedback according to participants' viewing patterns, in order to modify their attention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Attention Modification
Feedback according to participants' viewing patterns, in order to modify their attention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women between the ages of 18 and 65.
* Meeting a current diagnosis of Major Depressive Disorder (MDD) according to the DSM-IV
* MDD as the primary diagnosis: In cases of co-morbidity, MDD will be deemed as the most distressing and clinically significant condition among the co-morbid disorders
* Stable pharmaco-therapy: Participants receiving a pharmacological treatment who are taking a stable medication for at least 3 months before the beginning of the procedure.
Exclusion Criteria
* Co-morbidity with any neurological disorder (i.e., epilepsy, brain injury).
* Another psychotherapeutic treatment during the study.
* Usage of neuroleptic medication.
* Change in medication status during the study.
* Substantial usage of drugs or alcohol in the present time.
* Poor judgment capacity (i.e., children under 18 and special populations).
* High Risk of Suicide.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel Aviv University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yair Bar-Haim
Professor of Psychology and Neuroscience School of Psychological Sciences Sagol School of Neuroscience Tel Aviv University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yair Bar-Haim, Phd
Role: PRINCIPAL_INVESTIGATOR
Tel Aviv University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tel-Aviv University
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAUDEPI
Identifier Type: -
Identifier Source: org_study_id